73.51
2.67 (3.77%)
| Penutupan Terdahulu | 70.84 |
| Jumlah Dagangan | 296,925 |
| Harga / Pendapatan (P/E Ke hadapan) | 58.80 |
| Harga / Jualan (P/S) | 4.56 |
| Harga / Buku (P/B) | 33.58 |
| Julat 52 Minggu |
| Margin Keuntungan | -44.91% |
| Margin Operasi (TTM) | -33.55% |
| EPS Cair (TTM) | -2.70 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 183.70% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 21.13% |
| Nisbah Semasa (MRQ) | 5.57 |
| Aliran Tunai Operasi (OCF TTM) | -65.89 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -36.41 M |
| Pulangan Atas Aset (ROA TTM) | -16.05% |
| Pulangan Atas Ekuiti (ROE TTM) | -33.98% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Tarsus Pharmaceuticals, Inc. | Bercampur | Menaik |
AISkor Stockmoo
| Nilai 35% | 0.0 |
| AI Insight info | NA |
| Penilaian Relatif info | NA |
| Kesihatan Kewangan info | 0.0 |
| Masa 35% | -1.6 |
| AI Technical info | NA |
| Osilator Teknikal info | -2.0 |
| Purata Bergerak Teknikal info | -1.0 |
| Wang Pintar 30% | 0.0 |
| Konsensus Penganalisis info | 0.0 |
| Aktiviti Orang Dalam info | NA |
| Persekitaran | ×1.21 |
| Persekitaran Makro info | -3.3 |
| Sektor berbanding Pasaran (6B) | -22.5% |
| Persetujuan Tonggak | ×1.00 |
| Tidak dikira dalam skor | |
| Volatiliti Harga info | 0.8 |
| Skor Akhir | -0.68 |
|
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 3.25% |
| % Dimiliki oleh Institusi | 110.77% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Rtw Investments, Lp | 30 Jun 2026 | 3,357,059 |
| Paradigm Biocapital Advisors Lp | 30 Jun 2026 | 2,775,649 |
| Jennison Associates Llc | 30 Jun 2026 | 1,663,655 |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |